Evome Medical Technologies Inc. (LNDZF)

LNDZF Cash Flow Statement

Financials in millions CAD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Feb 28, 2022	Feb 28, 2021	Feb 29, 2020
Net Income	-23.53	-15.6	-19.08	-4.37	-2.67	-1.92
Depreciation & Amortization	3.87	4.51	2.17	0.84	-	0.05
Loss (Gain) From Sale of Investments	-	-	-	-0.02	0.18	0.06
Asset Writedown & Restructuring Costs	14.23	13.51	-	5.52	-	0.04
Provision for Credit Losses	0.58	0.69	-	-	-	0.02
Stock-Based Compensation	0.25	1.29	1.53	1.2	0.24	0.02
Change in Accounts Payable	-3.25	-0.97	2.25	1.52	0.88	-0.04
Change in Other Net Operating Assets	5.61	-4.6	2.51	-1.97	0.39	0.79
Other Operating Activities	5.8	-4.42	15.56	-6.55	-	0.57
Operating Cash Flow	5.4	-0.92	-0.99	-3.7	-0.98	-0.2
Capital Expenditures	-0.04	-0.2	-0.77	-0.06	-	-
Cash Acquisitions	-	-1.32	-5.66	-5.06	-	-
Sale (Purchase) of Intangibles	-	-	-0.29	-	-	-
Investment in Securities	-	-	-	0.5	0.07	-0.9
Investing Cash Flow	-0.04	-1.52	-6.72	-4.62	0.07	-0.9
Short-Term Debt Issued	-	0.95	-	1.55	-	-
Long-Term Debt Issued	-	-	-	0.94	-	-
Total Debt Issued	-0.2	0.95	-	2.49	-	-
Long-Term Debt Repaid	-	-0.16	-	-2.53	-	-
Total Debt Repaid	-5.88	-0.16	-0.98	-2.53	-	-
Net Debt Issued (Repaid)	-6.08	0.79	-0.98	-0.04	-	-
Issuance of Common Stock	-	0.03	0.27	4.64	5.43	-
Other Financing Activities	-	-	1.18	-0.66	-	-
Financing Cash Flow	-6.08	0.82	0.47	3.94	5.43	-
Foreign Exchange Rate Adjustments	1.07	0.6	-0.11	-0.06	-0.37	0.14
Net Cash Flow	0.36	-1.01	-7.35	-4.45	4.16	-0.95
Free Cash Flow	5.37	-1.12	-1.76	-3.76	-0.98	-0.2
Free Cash Flow Margin	11.83%	-1.87%	-4.45%	-20.97%	-	-59.10%
Free Cash Flow Per Share	0.06	-0.01	-0.03	-0.09	-0.03	-0.01
Cash Interest Paid	2.5	2.04	0.41	0.39	-	-
Cash Income Tax Paid	0.02	0.06	0.05	0.01	-	-

Updated Nov 25, 2024. Source: S&P Global Market Intelligence. Financial Services template. Financial Sources.